LinksHomepageStock List Search by Ticker News Login |
Ligand Pharmaceuticals Incorpor (NasdaqGM:LGND)
|
|
The following stock analysis is based on 10.4 years of data (i.e. since Oct 31, 2012). All the stock history has been downloaded.
Ligand Pharmaceuticals Incorpor trades on the NasdaqGM exchange in USD dollars.
It is in the sector.
It is currently trading at $71.4 ($72.11 the previous day).
The next reporting date is in 33 days (2023 05 03).
CNN estimates profits for the upcoming quarter will be $0.86 per share ($33.5M). The current Canada / US exchange rate is 1.3546.
Over the past 12 months, $206910 worth of shares have been purchased and $1999140 worth of shares have been sold by insiders.
The year over year average increase is -15.0% per year assuming steady exponential growth. The actual 5 year average is -4.26. Details on the individual increase in one year intervals is provided below.
| Past Performance | Average Price | Percent Change | |
|---|---|---|---|
| 1 year | 82.983521212121 | -35 | - Below Average |
| 2 year | 127.65277619048 | 13.1 | + Above Average |
| 3 year | 112.82003307087 | 11.8 | + Above Average |
| 4 year | 100.92081235955 | -42.6 | - Below Average |
| 5 year | 175.73384030418 | 31.4 | + Above Average |
The worst drop it has had in recent years is -77.4%. It has a up and down shape to the stock curve, which means the stock can have significant gains followed by losses. Good for day trading, but needs to be watched if held for any significant amount of time.
| DAYS AG0 | PRICE | |
| 10 | 72.16 | DROPPING |
| 30 | 71.48 | RISING |
| 60 | 69.83 | RISING |
| 150 | 87.6725 | DROPPING |
| 365 | 112.58 | DROPPING |
| 800 | 123.34 | DROPPING |
| 1200 | 106.84 | RISING |
| 1600 | 158.59 | DROPPING |
| 2000 | 140.14 | RISING |
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala PharmaceuticalsWed, 22 Mar 2023 11:37:11 CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals are part of the Zacks Industry Outlook article.... Read Full Article |
Novartis (NVS) Oncology Drug Gets FDA Nod for Label ExpansionFri, 17 Mar 2023 17:24:05 Novartis (NVS) obtains FDAs approval for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for pediatric brain cancer.... Read Full Article |
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%Fri, 17 Mar 2023 14:13:02 Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.... Read Full Article |
How Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 49.11%Fri, 17 Mar 2023 13:55:01 The average of price targets set by Wall Street analysts indicates a potential upside of 49.1% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside ...... Read Full Article |
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid BiopsyThu, 09 Mar 2023 13:00:00 Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and ELAINE-2 Phase 2 study resultsSermonix anticipates dosing the first patient in first half of 2023 COLUMBUS, ...... Read Full Article |
Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 MutationMon, 06 Mar 2023 14:00:00 ST. LOUIS, March 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today announced that its lead drug candidate, lasofoxifene, improved vaginal/vulvar symptoms ...... Read Full Article |
Ligand Pharmaceuticals Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsFri, 03 Mar 2023 10:19:38 Ligand Pharmaceuticals ( NASDAQ:LGND ) Full Year 2022 Results Key Financial Results Revenue: US$196.2m (down 19% from...... Read Full Article |
Ligand's (LGND) Q4 Sales and Earnings Top, View Raised, Stock UpThu, 23 Feb 2023 12:49:12 Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.... Read Full Article |
Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue EstimatesThu, 23 Feb 2023 01:45:01 Ligand (LGND) delivered earnings and revenue surprises of 10.57% and 24.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article |
Ligand Reports Fourth Quarter and Full Year 2022 Financial ResultsWed, 22 Feb 2023 21:01:00 SAN DIEGO, February 22, 2023--Ligand Reports Fourth Quarter and Full Year 2022 Financial Results... Read Full Article |
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA NephropathyFri, 17 Feb 2023 23:30:00 SAN DIEGO, February 17, 2023--Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan)... Read Full Article |
Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical TrialThu, 16 Feb 2023 13:00:00 Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative™ today announced that Sermonix's investigational next-generation targeted endocrine therapy, lasofoxifene, will be evaluated in a new study arm of the ongoing I-SPY endocrine program sponsored by Quantum Leap. This portion of the ...... Read Full Article |
Strength Seen in Merus N.V. (MRUS): Can Its 12.6% Jump Turn into More Strength?Fri, 10 Feb 2023 08:44:08 Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.... Read Full Article |
Ligand to Report Fourth Quarter Financial Results on February 22Mon, 06 Feb 2023 21:01:00 SAN DIEGO, February 06, 2023--Ligand to Report Fourth Quarter Financial Results on February 22... Read Full Article |
Shareholders in Ligand Pharmaceuticals (NASDAQ:LGND) are in the red if they invested five years agoMon, 23 Jan 2023 11:37:35 Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both...... Read Full Article |
Are Options Traders Betting on a Big Move in Ligand (LGND) Stock?Wed, 11 Jan 2023 16:10:04 Investors need to pay close attention to Ligand (LGND) stock based on the movements in the options market lately.... Read Full Article |
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum ContagiosumFri, 06 Jan 2023 13:05:00 SAN DIEGO, January 06, 2023--Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum... Read Full Article |
LGND vs. INCY: Which Stock Should Value Investors Buy Now?Thu, 29 Dec 2022 16:40:04 LGND vs. INCY: Which Stock Is the Better Value Option?... Read Full Article |
Are Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?Mon, 19 Dec 2022 14:40:02 Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong ...... Read Full Article |
Ligand Pharma Issues Mixed Guidance For FY23Tue, 13 Dec 2022 19:47:26 At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its OmniAb antibody discovery business. Management also introduced 2023 financial guidance. Related: Ligand To Spin-Off ...... Read Full Article |